X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
staurosporine (4162) 4162
animals (4031) 4031
humans (3556) 3556
staurosporine - pharmacology (3493) 3493
protein kinase c - antagonists & inhibitors (2182) 2182
alkaloids - pharmacology (2099) 2099
enzyme inhibitors - pharmacology (2028) 2028
biochemistry & molecular biology (1967) 1967
apoptosis (1853) 1853
rats (1601) 1601
phosphorylation (1437) 1437
cells, cultured (1351) 1351
cell biology (1336) 1336
apoptosis - drug effects (1298) 1298
index medicus (1293) 1293
tetradecanoylphorbol acetate - pharmacology (1256) 1256
mice (1239) 1239
protein kinase c - metabolism (1197) 1197
activation (1073) 1073
male (1059) 1059
cell line (940) 940
protein-kinase-c (850) 850
signal transduction (808) 808
protein kinase c (794) 794
expression (785) 785
oncology (778) 778
dose-response relationship, drug (749) 749
tumor cells, cultured (748) 748
kinetics (735) 735
female (709) 709
pharmacology & pharmacy (688) 688
calcium - metabolism (644) 644
neurosciences (635) 635
staurosporine - analogs & derivatives (633) 633
cells (620) 620
enzyme activation (610) 610
in vitro techniques (582) 582
time factors (552) 552
cell line, tumor (533) 533
apoptosis - physiology (532) 532
caspases - metabolism (504) 504
protein kinase c - physiology (449) 449
enzyme activation - drug effects (444) 444
isoquinolines - pharmacology (442) 442
protein kinase inhibitors (438) 438
transfection (427) 427
inhibition (419) 419
molecular sequence data (413) 413
proteins (408) 408
biophysics (406) 406
signal transduction - drug effects (404) 404
death (399) 399
calcium (393) 393
physiology (384) 384
blotting, western (383) 383
rats, sprague-dawley (382) 382
antineoplastic agents - pharmacology (368) 368
piperazines - pharmacology (366) 366
cell survival - drug effects (363) 363
indoles - pharmacology (361) 361
research article (359) 359
cancer (353) 353
research (353) 353
immunology (345) 345
1--2-methylpiperazine (336) 336
amino acid sequence (323) 323
neurons - drug effects (319) 319
inhibitor (311) 311
protein-kinase (310) 310
cell death (306) 306
phorbol ester (303) 303
protein kinases (298) 298
caspase 3 (293) 293
protein (292) 292
hela cells (290) 290
analysis (287) 287
mutation (284) 284
in-vitro (281) 281
flow cytometry (280) 280
differentiation (278) 278
receptor (278) 278
induction (274) 274
mitochondria (272) 272
protein kinase-c (272) 272
protein kinases - metabolism (272) 272
cell division - drug effects (271) 271
physiological aspects (264) 264
rats, wistar (262) 262
cell-death (261) 261
phosphorylation - drug effects (258) 258
protein kinase inhibitors - pharmacology (257) 257
hematology (256) 256
gene expression (248) 248
down-regulation (247) 247
mitochondria - metabolism (243) 243
endocrinology & metabolism (242) 242
kinases (240) 240
protein-tyrosine kinases - antagonists & inhibitors (240) 240
inhibitors (238) 238
binding (237) 237
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7709) 7709
Chinese (44) 44
Russian (22) 22
Japanese (17) 17
French (10) 10
German (6) 6
Korean (6) 6
Spanish (2) 2
Ukrainian (2) 2
Persian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 454 - 464
Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,... 
TRIAL | INTERNAL TANDEM DUPLICATION | WILD-TYPE | MEDICINE, GENERAL & INTERNAL | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | DISTINCT | TYROSINE KINASE INHIBITOR | SORAFENIB | PHASE-I | YOUNGER | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2017, Volume 70, Issue 16, pp. C182 - C182
Methods The whole experiment was divided into control group, STS treatment group, BDMC pretreatment with STS treatment group and BDMC pretreatment group in the... 
Apoptosis | Cardiomyocytes | Staurosporine | Rodents
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 26, pp. 2530 - 2541
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 04/2012, Volume 122, Issue 4, pp. 1541 - 1552
Patients with triple-negative breast cancer (TNBC) - defined by lack of estrogen receptor and progesterone receptor expression as well as lack of human... 
SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | P53 MUTATION | CHECKPOINT KINASE-1 | PATHWAY | PROTEIN-KINASE | 7-HYDROXYSTAUROSPORINE UCN-01 | DNA-DAMAGE | S-PHASE | PREDICTIVE-VALUE | CDC25A PHOSPHATASE | Thiophenes - therapeutic use | Apoptosis - drug effects | Humans | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Receptors, Progesterone - genetics | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Camptothecin - administration & dosage | Antineoplastic Agents, Phytogenic - therapeutic use | Camptothecin - analogs & derivatives | Thiophenes - pharmacology | Tumor Suppressor Protein p53 - deficiency | Breast Neoplasms - drug therapy | DNA, Neoplasm - drug effects | Protein Kinase Inhibitors - administration & dosage | Urea - therapeutic use | Mice, Inbred NOD | Mice | DNA Damage | Cell Cycle - drug effects | Genes, cdc | Staurosporine - pharmacology | Urea - pharmacology | Staurosporine - administration & dosage | Neoplasm Proteins - physiology | Staurosporine - analogs & derivatives | Cell Line, Tumor - transplantation | Receptors, Estrogen - analysis | Thiophenes - administration & dosage | Molecular Targeted Therapy | Genes, p53 | Urea - analogs & derivatives | Female | Antineoplastic Agents - pharmacology | Cell Line, Tumor - metabolism | Urea - administration & dosage | Protein Kinases - drug effects | Receptors, Estrogen - genetics | Camptothecin - therapeutic use | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Genes, erbB-2 | Protein Kinase Inhibitors - therapeutic use | Staurosporine - therapeutic use | Protein Kinases - physiology | Checkpoint Kinase 1 | Neoplasm Proteins - analysis | Protein Kinase Inhibitors - pharmacology | Breast cancer | Genetic aspects | Research | Gene mutations | Health aspects | DNA damage | Estrogen | Càncer de mama | Ratolins (Animals de laboratori) | Apoptosi | Receptors d'hormones | Hormone receptors | Chemotherapy | Mice (Laboratory animals) | Progesterone | Quimioteràpia | Progesterona | Estrògens | Apoptosis
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2015, Volume 90, Issue 4, pp. 276 - 281
Journal Article
Journal Article